Tempus AI, Inc.

Tempus AI, Inc. (NASDAQ: TEM) is a technology-driven company focused on enhancing precision medicine through the applied use of artificial intelligence in healthcare. It provides AI-powered solutions that help physicians deliver personalized treatment to patients, while simultaneously supporting the discovery, development, and deployment of targeted therapeutics.

Positive Growth Aspects

• Strong Financial Momentum and Revenue Growth: Tempus AI, Inc. delivered exceptional financial performance in the second quarter of 2025, highlighted by a robust 89.6% year-over-year increase in total revenue to USD 314.6 million. The company’s Genomics segment led the growth, posting a 115.3% year-over-year surge to USD 241.8 million, driven by accelerating test volumes in both Oncology and Hereditary testing. Oncology revenue climbed 32.9% with a 26% volume increase, while Hereditary testing revenue rose 33.6% on a 32% volume boost, underscoring the company’s growing leadership in precision medicine. The Data and Services division also expanded by 35.7%, led by a 40.7% increase in data licensing revenues, reflecting the rising adoption of Tempus’ AI-driven data insights. Overall, gross profit surged 158.3% year-over-year to USD 195 million, demonstrating the scalability of its business model and improving operational leverage.
• Enhanced Financial Position and Operational Expansion: The company strengthened its financial flexibility through the issuance of USD 750 million in 0.75% convertible senior notes, enabling it to refinance higher-cost debt and reduce future interest expenses. Tempus also ended the quarter with USD 293 million in cash and marketable securities, a USD 70 million sequential improvement, providing a solid liquidity buffer for future investments. On the operational front, Tempus expanded its AI-powered clinical tools, including the extension of Tempus Next™ into breast cancer and integration of Tempus One™ into major EHR systems, enhancing point-of-care decision support. Additionally, its xM™ liquid biopsy assay and expanded Personalis collaboration further cemented its position in precision oncology monitoring. The company’s database now surpasses 350 petabytes of connected clinical and molecular data, integrating over 40 million clinical records and 4 million sequenced samples, reinforcing its competitive moat in AI-enabled genomics and healthcare analytics.

Growth Challenges

• Persistent Losses and Margin Pressures: Despite notable revenue and margin gains, Tempus AI continues to operate at a net loss of USD 42.8 million in the second quarter of 2025. While this represents a substantial improvement over the prior year’s USD 552.2 million loss, the company remains in the red, reflecting high operating expenses and ongoing investments in R&D and commercialization. The adjusted EBITDA loss of USD 5.6 million, though 82% better than last year, indicates that Tempus has yet to achieve sustainable profitability. Moreover, the issuance of convertible notes, while beneficial for cash flow and debt refinancing, will lead to increased interest expenses and potential shareholder dilution in the long term. These factors suggest that achieving consistent positive earnings remains a medium-term challenge.
• Execution and Integration Risks in Expansion Strategy: As Tempus broadens its AI and genomics ecosystem, it faces execution risks related to large-scale integration of new technologies and partnerships. Expanding into new therapeutic areas like breast and colorectal cancer, alongside managing a rapidly growing data infrastructure exceeding 350 petabytes, introduces significant operational complexity. The company’s reliance on high R&D spending and continuous innovation to maintain competitive advantage could pressure short-term margins. Furthermore, its aggressive growth trajectory, including integrating acquisitions such as Ambry Genetics, requires seamless alignment of operations and data systems to fully capture synergies. While Tempus’ long-term vision remains compelling, short-term volatility in profitability and execution precision will be critical factors to monitor as the company scales toward sustained profitability.

Technical Observation (on the daily chart):

Tempus AI's stock is exhibiting a sustained uptrend, with prices remaining above the 50-day moving average, signaling ongoing medium-term strength despite recent consolidation below the 20-day moving average. However, a break below the 50-day moving average would strengthen bearish momentum and deepen weakness in the stock. The RSI, hovering near 50, indicates neutral momentum and reflects indecisiveness at current levels. Overall, the trend remains positive, with support around USD 85, and there is potential for a bullish continuation if the price breaks above USD 92.

Tempus AI, Inc. delivered a strong second quarter in 2025 with robust revenue growth of 89.6% year-over-year and a 158% surge in gross profit, driven by accelerating volumes in its Genomics and Data segments and expanding adoption of its AI-powered clinical tools. The company’s strengthened balance sheet through a USD 750 million convertible note offering and a growing cash position also underscore improving financial flexibility. However, despite narrowing its net loss to USD 42.8 million and achieving significant EBITDA improvement, Tempus remains unprofitable, facing ongoing margin pressures from high R&D and operational expenses. While its expanding AI and data ecosystem positions it as a leader in precision medicine, the path to sustainable profitability and execution consistency remains an important challenge.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Tempus AI, Inc. (NASDAQ: TEM) at the close market price of USD 86.27 as of Oct 30,2025.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 30,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.